Terms: = Lymphoma AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
2403 results:
1. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantations: A single-center experience.
Aygüneş U; Karagün BŞ; Şaşmaz I; Antmen AB
Clin Transplant; 2024 May; 38(5):e15366. PubMed ID: 38775798
[TBL] [Abstract] [Full Text] [Related]
2. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Haderk F; Chou YT; Cech L; Fernández-Méndez C; Yu J; Olivas V; Meraz IM; Barbosa Rabago D; Kerr DL; Gomez C; Allegakoen DV; Guan J; Shah KN; Herrington KA; Gbenedio OM; Nanjo S; Majidi M; Tamaki W; Pourmoghadam YK; Rotow JK; McCoach CE; Riess JW; Gutkind JS; Tang TT; Post L; Huang B; Santisteban P; Goodarzi H; Bandyopadhyay S; Kuo CJ; Roose JP; Wu W; Blakely CM; Roth JA; Bivona TG
Nat Commun; 2024 May; 15(1):3741. PubMed ID: 38702301
[TBL] [Abstract] [Full Text] [Related]
3. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
4. Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19 Pandemic: A Cluster Randomized Clinical Trial.
Meredith LS; Ahluwalia S; Chen PG; Dong L; Farmer CM; Bouskill KE; Dalton S; Qureshi N; Blagg T; Timmins G; Schulson LB; Huilgol SS; Han B; Williamson S; Watson P; Schnurr PP; Martineau M; Davis K; Cassells A; Tobin JN; Gidengil C
JAMA Netw Open; 2024 Apr; 7(4):e244192. PubMed ID: 38687482
[TBL] [Abstract] [Full Text] [Related]
5. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to alk inhibitors in alk-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract] [Full Text] [Related]
6. Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report.
Yan X; Ren W; Li S; Zhu Z; Gao L; Zhi K
BMC Oral Health; 2024 Apr; 24(1):470. PubMed ID: 38637781
[TBL] [Abstract] [Full Text] [Related]
7. Reclassification of a spindle cell sarcoma after identification of a tfg-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract] [Full Text] [Related]
8. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with alk fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract] [Full Text] [Related]
9. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or alk Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
10. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract] [Full Text] [Related]
11. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
Tong D; Chisholm J; Madden B; Ahmed M
J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
[TBL] [Abstract] [Full Text] [Related]
12. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory alk-positive anaplastic large cell lymphoma].
Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
[TBL] [Abstract] [Full Text] [Related]
13. New treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
14. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract] [Full Text] [Related]
15. Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of alk and MEK Inhibitors: A Systematic Review From the Children's Oncology Group.
Fisher B; Meyer A; Brown A; Conway Keller M; McKeown T; Tiller J; Saylor KM; Duffy EA
J Pediatr Hematol Oncol Nurs; 2024; 41(2):114-128. PubMed ID: 38549368
[No Abstract] [Full Text] [Related]
16. Concurrent inhibition of alk and SRC kinases disrupts the alk lung tumor cell proteome.
Diaz-Jimenez A; Ramos M; Helm B; Chocarro S; Frey DL; Agrawal S; Somogyi K; Klingmüller U; Lu J; Sotillo R
Drug Resist Updat; 2024 May; 74():101081. PubMed ID: 38521003
[TBL] [Abstract] [Full Text] [Related]
17. Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.
Wang J; Ying J; Wang Z; Meng X; Wu M; Qian C
Ann Palliat Med; 2024 Mar; 13(2):221-229. PubMed ID: 38509647
[TBL] [Abstract] [Full Text] [Related]
18. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
19. [Chinese expert consensus on iruplinalkib for the treatment of locally advanced or metastatic alk-positive non-small cell lung cancer (2024 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):189-205. PubMed ID: 38494766
[TBL] [Abstract] [Full Text] [Related]
20. Survival benefit in EGFR-wild and alk negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract] [Full Text] [Related]
[Next]
